Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Fatma Sen, MDa, Makbule Tambas, MDh*, Kubra Ozkaya, MDi, Murat Emin Guvell, MDj, Rumeysa Ciftci, MDa, Berker Ozkan, MDk, Ethem Nezih Oral, MDl, Esra Kaytanci Saglam, MDm, Pinar Saip, MDn, Alper Toker, MDo, Adalet Demir, MDP, Pinar Firat, MDq, Adnan Aydiner, MDa, Yesim Eralp, MDa

Abstract
Presently, there is no consensus regarding which chemotherapy regimen is best to administer with radiotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). Herein, our aim was to compare the outcome of patients treated with either etoposide-cisplatin (EP) or docetaxel-cisplatin (DP) in this curative setting.

Patients treated with either EP or DP and concurrent radiotherapy from 2004 to 2012 were identified and their detailed medical records and follow-up information were obtained for analysis in this retrospective study. Survival rates were compared using Cox proportional hazards regression models with adjustments for confounding parameters provided by propensity score methods.

A total of 105 patients were treated with concurrent chemoradiotherapy for LA-NSCLC (stage IIB-IIIA-IIIB). The median ages were 54 years (range, 32–70 years) and 55 years (range, 37–73 years) in the EP (n = 50) and DP (n = 55) groups, respectively. The median follow-up time was 27 months (range, 1–132 months) in the EP group and 19 months (range, 1–96 months) in DP group. There was no significant difference in baseline clinicopathologic features including age, sex, performance status, histologic subtype, and clinical TNM stages between groups. In the univariate analysis, the median overall survival of patients treated with EP was higher than that of patients treated with DP (41 vs. 20 months, P = 0.003). Multivariate analysis further revealed a survival advantage with EP compared with DP (hazard ratio [HR], 0.46; 95% confidence interval: 0.25–0.83; P = 0.009). The toxicity profile of the 2 treatment groups was similar except that pulmonary toxicity was higher in the DP group (grade 3–4: 0% vs. 6%, P = 0.024).

Concurrent chemoradiotherapy with EP may provide more favorable outcomes than DP and with an acceptable safety profile.

Abbreviations: DP = docetaxel-cisplatin, EP = etoposide-cisplatin, LA-NSCLC = locally advanced non-small-cell lung cancer, PC = carboplatin/paclitaxel, PV = cisplatin/vinblastin.

Keywords: concomitant chemoradiotherapy, docetaxel-cisplatin, etoposide-cisplatin, locally-advanced NSCLC, lung cancer

1. Introduction
The primary cause of cancer death is lung cancer. The estimated new cases and deaths because of lung cancer in the United States in 2015 were 221,200 and 158,040, respectively,[1] whereas the 5-year survival rate for patients with lung cancer is 17.4%.[2] Including small-cell lung carcinoma, only 37% of lung cancer is diagnosed while it is still confined to the primary site or spread to regional lymph nodes or directly surrounding tissues; 5-year survival rates for patients with localized and regional tumors are 54% and 26.5%, respectively.[2] It is essential to manage the disease locoregionally to increase the survival rates of patients who have locally advanced disease (LA-NSCLC) with no distant metastasis.

Although the management of localized or metastatic disease is well established, there are major ongoing controversies for locally advanced disease. Although randomized trials failed to show any survival benefit provided by surgery in stage IIIA disease, surgery may be still an option for patients with single N2 node (<3 cm).[3–11] For the remaining patients, neoadjuvant chemoradiotherapy (CRT) or chemotherapy (CT) is recommended, whereas in cases with multiple >3-cm pathologically proven malignant lymph nodes, definitive CRT is more convenient.[6] Furthermore, a recently published meta-analysis that included 7 trials with 1049 patients revealed that neoadjuvant CT/CRT followed by surgery was not superior to neoadjuvant CT/CRT followed by radical RT in patients with stage IIIA disease.[7]
The combined CRT was shown to be superior to RT alone in unresectable stage IIIA–IIIB NSCLC in several studies. In addition, concurrent CRT is more effective than sequential CRT at the expense of an increase in grade 3–4 esophagitis. However, one of the main debates centers on which CT regimen is more effective with concomitant CRT. To date, the suggested CT regimens for all histologies include cisplatin/etoposide (EP), cisplatin/vinblastine (PV), and carboplatin/paclitaxel (PC), and a platin combination with pemetrexed may be used for patients with nonsquamous NSCLC. Nevertheless, there is no current consensus on which CT regimen is the best to administer concomitantly with RT in patients with LA-NSCLC.

Randomized trials regarding this subject mainly included PE or PV regimens. Several recent studies compared PE with PC in terms of efficiency and produced conflicting results. However, docetaxel is a third-generation CT agent and its effectiveness has been demonstrated in many studies indicating that the docetaxel-cisplatin (DP) regimen was equal or superior to a PV combination. In addition, docetaxel proved its superiority to vinca-alkaloids in combinations in both metastatic and LA-NSCLC. Furthermore, a meta-analysis revealed that docetaxel-based CT provided longer survival than vinca alkaloid-containing regimens.

The phase II Southwest Oncology Group S9504 trial, which added docetaxel consolidation to concomitant EP, notified a median survival of 26 months. However, no studies have compared EP regimen with DP in LA-NSCLC. The only trial that compared EP with a cisplatin-taxane combination including paclitaxel but not docetaxel was conducted by the Eastern Cooperative Oncology Group. Their study comprised 599 patients with stage IIIB-IV NSCLC who received either EP or a cisplatin-paclitaxel regimen; the authors reported a survival benefit in favor of paclitaxel. Nevertheless, the efficacy of DP over EP still remains unknown. Thus, we conducted the present study to address the question as to whether DP is superior to EP in patients with LA-NSCLC who are concurrently treated with CRT in terms of survival and safety.

2. Material and methods

2.1. Study design and eligibility criteria

The medical records of approximately 10,000 patients with lung cancer who were referred to Istanbul University Institute of Oncology from 2004 to 2012 were evaluated. Among them, patients with stage IIIA, IIIB, or IIIB histopathologically confirmed NSCLC whose medical records were available in detail were included in the study. The 10th edition of American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) system was used while staging according to radiologic and pathologic findings. Adverse effects were evaluated based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.

The treatment decision was taken by a multidisciplinary team that included a medical oncologist, radiation oncologist, pathologist, chest disease specialist, thoracic surgeon, radiologist, and a nuclear medicine specialist. Patients who were inoperable were treated with radical CRT, CRT followed by consolidation CT, or induction CT followed by CRT. Patients whose tumors were too large for radiotherapy (RT) received induction CT. All patients were evaluated for surgery eligibility at each step. Patients who became operable underwent surgery including lobectomy, bilobectomy, or pneumonectomy.

The pretreatment evaluation included a detailed clinical history and physical examination with a series of biochemistry tests and complete blood cell counts. Selection for treatment required an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2, and appropriate bone marrow (absolute neutrophil count >1500 cells/μL, and platelet count >100,000 cells/μL), and cardiac, renal, and hepatic function.

Patients were treated with either etoposide (30 mg/m² on days 1–5 and 29–33) and cisplatin (50 mg/m² on days 1, 8, 29, and 36) (EP) or 6 cycles of weekly DP (each 20 mg/m²) concurrently with radiotherapy up to a 60 Gy. Linear accelerators (Simens/Oncor Impression, Varian DBX 600C and Varian Trilogy-Rapid arc) with a 6 to 15 MV photon beam were used for radiotherapy. All patients underwent 3-dimensional treatment planning using either CMS-XIO (CMS Inc, St Louis, MO) or Varian Eclipse TPS station version 8.9 (Varian Medical Systems, Palo Alto, CA) treatment planning systems. Treatment planning was based on CT scans with 5-mm section thickness and 5-mm intervals obtained in a treatment position. Customized devices were used to immobilize the patients. Radiotherapy was administered with an angled field technique to include the entire planning tumor volume (PTV) in the isodose 95% area. Gross tumor volume (GTV) was defined as tumor extension and metastatic lymph nodes. The clinical target volume (CTV) was GTV plus a 1-cm margin. PTV consisted of CTV plus 1 cm to the superior-inferior direction and 0.5 cm to the anterior-posterior and left-right directions. The median total dose was 60 Gy/2 Gy/d.

All patients had pretreatment imaging of primary tumors with magnetic resonance imaging (MRI) or computed tomography. For patients with evaluable imaging studies before and after treatment, radiologic response was recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST) or PET Response Criteria in Solid Tumors (PERCIST), and classified as follows: complete response (CR), partial response (PR), stable disease (SD), or progressive disease. Disease follow-up programs included physical examination, laboratory tests, and computed tomography scan or MRI depending on which imaging methods were indicated, and performed every 3 months for the first 2 years, every 6 months for the following 3 years, and annually thereafter with no anticancer treatment.

Baseline characteristics of patients and diseases including age, sex, weight loss, ECOG performance status, histologic type, clinical T and N stages, as well as treatment type, CT regimen, operability, progression during follow-up, metastasis, hematologic and nonhematologic adverse effects of treatment were obtained retrospectively in detail for all patients from their medical records.

All procedures performed in studies involving human participants were in accordance with the ethics standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethics standards. Formal consent is not required for this type of study.

2.2. Statistical analysis

The Statistical Package for the Social Sciences (SPSS) for Windows version 16.0 (SPSS Inc., Chicago, IL) was used for data analysis. Continuous variables were categorized using median values as cutoff points. Student t test was used to compare continuous variables between the groups, and χ² and/or Kruskal–Wallis tests were performed for the comparison of categorical variables.

Overall survival (OS) was calculated from the date of first admission to disease-related death or date of last contact with the patient or any family member. Progression-free survival (PFS) was calculated from the date of admission to the date of first radiologic progression. Kaplan–Meier analysis was performed
for the estimation of survival distribution and differences in PFS and OS. The log-rank test was used to assess statistical significance in univariate comparisons. To adjust for potential covariate effects, Cox proportional hazards regression was used as the modeling paradigm. Multivariate analysis was conducted using Cox regression modeling. All statistical tests were 2-sided and a P value < 0.05 was considered statistically significant.

3. Results

In total, 50 patients (median age 54 years; range, 32–70 years) who were given concurrent EP, and 55 patients (median age 55 years; range, 37–73 years) who were given concurrent DP were enrolled in the analyses. There was no statistically significant difference in baseline clinicopathologic features including age (P = 0.41), sex (P = 0.33), weight loss (P = 0.20), ECOG performance status (P = 0.19), histologic type (P = 0.38), lung site (P = 0.35), clinical T and N stage (P = 0.59 and P = 0.12, respectively), disease stage (P = 0.96), surgery (P = 0.30), radiation dose (< 60 vs. ≥ 60 Gy) (P = 0.95), and treatment response (P = 0.99) between the groups. However, the mean radiation dose was higher in the EP group compared with the DP group (59 vs. 54 Gy; P = 0.02). In addition, induction or consolidation CT administration was more common in the DP group than in the EP group (84% vs. 34%; P < 0.001). The comparison of baseline characteristics of patients and treatment details of the 2 groups is shown in Table 1.

| Variable                      | Etoposide and cisplatin | Docetaxel and cisplatin | P    |
|-------------------------------|-------------------------|--------------------------|------|
| Age                           | Median                  | N                       | N    | 0.41 |
| Min-max                       | 32–70                   | 54                       | 55   | 0.41 |
| Sex                           | Male                    | 46                       | 53   | 0.96 |
|                               | Female                  | 4                        | 2    | 0.4  |
| Weight loss                   | Yes                     | 15                       | 10   | 0.19 |
|                               | No                      | 35                       | 42   | 0.81 |
| ECOG PS                       | 0                       | 21                       | 30   | 0.55 |
|                               | 1+                      | 29                       | 25   | 0.45 |
| Histological type             | Squamous                | 24                       | 25   | 0.46 |
|                               | Non-squamous            | 16                       | 13   | 0.24 |
|                               | NSCLC-NOS               | 10                       | 17   | 0.30 |
| Lung                          | Right                   | 29                       | 33   | 0.64 |
|                               | Left                    | 21                       | 19   | 0.36 |
| Clinical T stage              | T1–T3                   | 36                       | 31   | 0.57 |
|                               | T4                      | 14                       | 23   | 0.43 |
| Clinical N stage              | N0                      | 8                        | 12   | 0.19 |
|                               | N1                      | 2                        | 2    | 0.04 |
|                               | N2                      | 30                       | 34   | 0.62 |
|                               | N3                      | 10                       | 6    | 0.15 |
| Stage                         | IB                      | 29                       | 32   | 0.58 |
|                               | IB-III A                | 21                       | 23   | 0.42 |
| Surgery                       | Yes                     | 12                       | 9    | 0.16 |
|                               | No                      | 37                       | 46   | 0.84 |
| Radiation dose                | Mean (Gy)               | 59                       | 54   | 0.028|
|                               | Median± SD (Gy)         | 60±6.8                   | 60±11.2 | 0.028|
| Radiation dose                | < 60 Gy                 | 38                       | 39   | 0.76 |
|                               | ≥ 60 Gy                 | 12                       | 12   | 0.76 |
| Induction or consolidation therapy | Yes                      | 17                       | 46   | 0.84 |
|                               | No                      | 33                       | 9    | 0.16 |
| Treatment response            | Responders (PR + CR)    | 39                       | 43   | 0.80 |
|                               | Nonresponders (SD + PD) | 10                       | 11   | 0.20 |

CR = complete response, NSCLC = non-small-cell lung cancer, PD = progressive disease, PR = partial response, SD = standard deviation.
The median (min–max) follow-up time of patients was 27 months (range, 1–132 months) in the EP group and 19 months (range, 1–96 months) in the DP group. In the univariate analysis, median PFS of patients treated with EP was found higher than that of patients treated with DP (PFS=19 months, 95% confidence interval [CI] 4–34 vs. 10 months 95% CI 5–12; \( P=0.029 \)) (Table 2), as well as in patients with treatment response (PFS=22 months, 95% CI 11–33 vs. 6 months 95% CI 4–8; \( P<0.001 \)).

In the univariate analysis, the median OS of patients treated with EP was found higher than that of patients treated with DP (OS=41 months; 95% CI 26–56 vs. 20 months, 95% CI 14–26; \( P=0.003 \)) (Fig. 1). Furthermore, right-sided tumor (OS=30 months; 95% CI 16–44 vs. 19 months, 95% CI 12–26; \( P=0.029 \)), surgery performance (OS=52 months; 95% CI 13–92 vs. 23 months, 95% CI 20–26; \( P=0.023 \)), and treatment response (OS=40 months; 95% CI 29–83 vs. 17 months, 95% CI 17–21; \( P<0.001 \)) were detected associated with longer OS time in the univariate analysis. There was no statistical significance in terms of age (\( P=0.07 \)), sex (\( P=0.98 \)), weight loss (\( P=0.68 \)), ECOG performance status (\( P=0.51 \)), histologic type (\( P=0.63 \)), clinical T and N stage (\( P=0.33 \) and \( P=0.32 \), respectively), disease stage (\( P=0.45 \)), induction or consolidation therapy (\( P=0.06 \)), and radiation dose (\( P=0.12 \)) (Fig. 1). Further analyses revealed survival advantage with EP compared with DP (hazard ratio [HR]=0.46; 95% CI 0.25–0.83; \( P=0.009 \)). Significant variables were stratified with respect to potential confounding factors such as age, weight loss, T stage, histology, and stage of nodal involvement. In addition, both right-sided tumors (HR=0.38; 95% CI 0.35–0.98; \( P=0.041 \)) and treatment response (HR=0.26; 95% CI 0.15–0.48; \( P<0.001 \)) were found correlated with better survival time. Neither surgery (HR=0.65; 95% CI 0.32–1.28; \( P=0.22 \)), nor induction or consolidation therapy was associated with survival in the multivariate analysis (HR=0.84; 95% CI 0.54–1.65; \( P=0.94 \)). The results of multivariate analysis are shown in Table 4.

The toxicity profile of 2 treatment groups including anemia (\( P=0.91 \)), thrombocytopenia (\( P=0.47 \)), nausea/vomiting (\( P=0.69 \)), esophagitis (\( P=0.69 \)), neurotoxicity (\( P=0.20 \)), nephrotoxicity (\( P=0.38 \)), hepatotoxicity (\( P=0.37 \)), and diarrhea (\( P=0.76 \)) was found similar except that pulmonary (grade 3–4: 0% vs. 6%, \( P=0.02 \)) and skin toxicities (grade 1–2: 4% vs. 24%, \( P=0.01 \)) were higher in the DP group compared with EP. Although neutropenia incidence was slightly higher in the EP group than with DP (grade 3, 8% vs. 0%, \( P=0.055 \)), the infection rate was similar between the 2 groups (grade 3–4, 0% vs. 6%, \( P=0.08 \)). Detailed toxicity comparisons of the 2 groups are represented in Table 5.

### 4. Discussion

There are several CT combinations choices to consider for concomitant treatment, among which the most accepted and

---

**Table 2**

Univariate analysis of progression free survival of patients.

| Variable                        | No. of events | Median PFS, mo | Univariate analysis |
|---------------------------------|---------------|----------------|---------------------|
|                                 |               |                | 95% CI              | \( P \) |
| Concurrent chemotherapy         |               |                |                     | |
| E + P                           | 30/49         | 19             | 3.75–34.24          | 0.021 |
| D + P                           | 44/54         | 10             | 5.48–12.51          |      |
| Age, y                          |               |                |                     | |
| \( \leq 55 \)                   | 40/58         | 15             | 8.39–21.60          | 0.41  |
| > 55                            | 34/45         | 13             | 6.44–19.55          |      |
| Sex                             |               |                |                     | |
| Male                            | 70/97         | 13             | 6.71–19.29          | 0.73  |
| Female                          | 4/6           | 13             | 0–35.164            |      |
| Weight loss                     |               |                |                     | |
| Yes                             | 17/25         | 9              | 5.32–12.67          | 0.84  |
| No                              | 55/76         | 16             | 9.93–22.06          |      |
| ECOG PS                         |               |                |                     | |
| 0                               | 32/49         | 11             | 8.05–13.94          | 0.38  |
| 1+                              | 42/54         | 18             | 10.81–25.18         |      |
| Histological type               |               |                |                     | |
| Squamous                        | 29/48         | 19             | 0–42.35             |      |
| Non-squamous                    | 25/29         | 11             | 6.78–15.21          | 0.11  |
| NSCLC-NOS                       | 20/26         | 9              | 4–13.99             |      |
| Lung                            |               |                |                     | |
| Right                           | 42/61         | 18             | 6.10–29.89          | 0.12  |
| Left                            | 30/41         | 10             | 7.41–12.59          |      |
| Surgery                         |               |                |                     | |
| No                              | 6/81          | 13             | 6.20–19.79          | 0.09  |
| Yes                             | 13/21         | 35             | 0–80                |      |
| Clinical T stage                |               |                |                     | |
| T1–3                            | 44/65         | 16             | 8.26–23.73          | 0.11  |
| T4                              | 30/37         | 10             | 5.11–14.88          |      |
| Clinical N stage                |               |                |                     | |
| N0                              | 13/19         | 6              | 1.73–10.26          | 0.33  |
| N1                              | 2/4           | 35             |                     |      |
| N2                              | 45/63         | 18             | 12.41–23.58         |      |
| N3                              | 14/16         | 9              | 5.08–12.92          |      |
| Stage                           |               |                |                     | |
| IIB                              | 39/59         | 15             | 7.47–22.52          | 0.29  |
| IIB-IIA                         | 34/43         | 13             | 4.36–21.66          |      |
| Treatment response              |               |                |                     | |
| Yes                             | 52/80         | 22             | 11.05–32.94         | <0.001|
| No                              | 21/21         | 6              | 4.22–7.78           |      |
| Induction or consolidation therapy | 47/61    | 13             | 8.76–17.23          | 0.26  |
| No                              | 27/42         | 19             | 4.66–33.33          |      |
| Radiation dose                  |               |                |                     | |
| <60 Gy                          | 21/29         | 11             | 0.62–21.37          | 0.55  |
| \( \geq 60 \) Gy                | 70/99         | 16             | 9.57–22.43          |      |

\[ \text{CI} = \text{confidence interval}; \text{NSCLC-NOS} = \text{non-small-cell lung cancer}; \text{PFS} = \text{progression-free-survival} \]
Commonly used is EP.\(^{19}\) The other frequent options are combinations of platin with taxanes and vinorelbine; however, the best remains to be elucidated because of a lack of large, randomized trials.\(^{19}\) Nonetheless, there is some evidence for which combination might be more effective. For instance, in a meta-analysis by Shen et al.\(^{31}\) that included 9 randomized trials,\(^{19}\) the combination of platin with taxanes and vinorelbine; however, the most commonly preferred platin–taxane regimen in North America and some parts of Europe is CP.\(^{19}\) Santana-Davila et al\(^{31}\) reported that CP was as effective as EP regimen based on the data of the large database of the Veterans Health Administration. However, the results of the only randomized trial that compared EP with CP showed that EP provided higher survival time and less pulmonary but higher hematologic toxicity than EP, which is fully compatible with our results.\(^{12}\)

The conflicting results of these 2 studies gave rise to the following question in our minds: “Was the superiority of the EP regimen over CP combination caused by the superiority of cisplatin over carboplatin in the study of Wang et al?”. Because the Lung Adjuvant Cisplatin Evaluation meta-analysis demonstrated that carboplatin was not as efficient as cisplatin at eliminating micrometastasis in the adjuvant setting of stage II and III NSCLC.\(^{33}\) Accordingly, we decided to compare 2 cisplatin-containing regimens with standard etoposide or docetaxel, and our results indicated that EP was still superior to DP, which verified the findings of Wang et al.\(^{31}\)

Concurrent chemoradiotherapy with EP may provide more favorable outcomes than that of DP with a better safety profile. This finding is similar to those previously reported in the literature.\(^{22}\) The median OS and PFS achieved with EP in our group of patients were 40 months and 19 months, respectively, which were considerably higher compared without comes reported in the INT 139-patient trial (23.6 months and 12.8 months, respectively) that used the same CT protocol.\(^{3}\) Furthermore, both CT regimens resulted in median OS rates that were better than expected on the basis of data from previously reported studies in patients with stage III NSCLC.\(^{29}\) The reason for this inconsistency may be related to the fact that patients enrolled in our study with mediastinal nodal (N2) or N3 involvement were judged to be eligible for this inconsistency may be related to the fact that patients enrolled in our study with mediastinal nodal (N2) or N3 involvement were judged to be eligible for the study of Wang et al.\(^{20}\) The current controversies continue as to whether standard EP regimen is superior to a platin plus taxane combination. The most commonly preferred platin–taxane regimen in North America and some parts of Europe is CP.\(^{19}\) Santana-Davila et al\(^{31}\) reported that CP was as effective as EP.
Among the third-generation agents used with radiation in current practice, docetaxel might be the most toxic. This drug has resulted in a relatively high rate of serious pulmonary toxicity reported to occur in as many as 47% of patients treated concurrently with radiotherapy. In our study, the frequency (6%) of severe pulmonary toxicity seen who received EP concomitantly, which is similar to previous reports. The incidence of severe neutropenia and thrombocytopenia was considerably lower in our study (12% and 0%, respectively) compared with other studies including PE regimen (39% vs. 10%). Variations in terms of efficiency and toxicity have been reported between different nations receiving the same CT regimen. These differences mainly emerge from ethnic instabilities in single-nucleotide polymorphism distributions that affect CT transport and metabolism. It is well-established that the pharmocogenomic variability in genes may result in inter-racial and individual disparity concerning toxicity and outcomes. Our population comprised only Turkish patients; however, no pharmocogenomic study has investigated the distribution of gene polymorphisms in the Turkish population. Additionally, severe skin toxicity was not observed in any of the treatment arms; however, grade 2 skin toxicity was more frequent in patients who received DP (12% vs. 0%, P = 0.017). Increased cutaneous toxicity with docetaxel has been reported, especially in patients with breast cancer. The present study is a nonrandomized, retrospective study, which caused some limitations. First, the population of our study mainly consisted of men (>90%). The incidence of NSCLC has increased recently, and the rate of women diagnosed with NSCLC is about 35% to 40%. Second, >45% of patients had squamous cell lung cancer in the present study, whereas adenocarcinoma histology is the most common subtype among patients with LA-NSCLC referred to oncology centers. Last, the number of patients is relatively small.

5. Conclusions

In conclusion, we reported the toxicities and clinical outcomes of patients with unresectable stage III NSCLC treated with concurrent thoracic RT with either PE or DP. Given that PE provided better outcomes with less pulmonary but greater hematologic toxicity, we believe that PE might be more appropriate to administer concomitantly with close monitoring for neutropenia. Still, the results of our study warrant further investigation in randomized studies to make a final decision.

Acknowledgments

We would like to thank Mr. David F. Chapman who is a native-English speaker with scientific expertise for editing the language of the manuscript.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin 2015;65:5–29.
[2] Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD:National Cancer Institute; 2015.
[3] Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379–86.
[4] van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442–50.
[5] Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) non-small-cell lung cancer. Ann Thorac Surg 2008;86:362–6. discussion 366–367.
[6] Higgins K, Chino JP, Marks LB, et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;75:1462–7.
[7] Xu YP, Li B, Xu XL, et al. Is there a survival benefit in patients with stage IIA (N2) non-small cell lung cancer receiving neoadjuvant chemotherapy and/or radiotherapy prior to surgical resection: a systematic review and meta-analysis. Medicine 2015;94:879–88.
[8] Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940–9.

[9] Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417–23.

[10] Curran W Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452–60.

[11] Asuper A, Le Peuchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181–90.

[12] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187–99.

[13] Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non-small cell lung carcinoma: a modified phase III trial. Cancer 2001;92:1213–23.

[14] Santana-Davila R, Devinetty K, Szabo A, et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol 2015;33:567–74.

[15] Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002;20:3454–60.

[16] Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883–91.

[17] Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 2011;29:3120–5.

[18] Vokes EE, Senan S, Treat JA, et al. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemoradiotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009;10:193–8.

[19] Vansteenkiste J, De Ryruyscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):i89–98.

[20] Wang L, Wu S, Ou G, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2012;77:89–96.

[21] Machay M, Lee JH, Stevenson JP, et al. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. J Thorac Cardiovasc Surg 2004;127:108–13.

[22] Liew MS, Sai J, Starnams MH, et al. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/paclitaxel in stage III non-small cell lung cancer. Cancer Med 2013;2:916–24.

[23] Fossella F, Pereira Jr, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016–24.

[24] Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005;104:2766–74.

[25] Tan EH, Rolski J, Grozhik T, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomized multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009;20:1249–56.

[26] Kim YH, Kim JS, Choi YH, et al. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer. Int J Clin Oncol 2002;7:114–9.

[27] Kubota K, Watanabe K, Kubo H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:2534–61.

[28] Douillard JY, Laporte S, Fossella F, et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007. 939–46.

[29] Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study 9504. J Clin Oncol 2003;21:2004–10.

[30] Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623–31.

[31] Shen G, Bian G, Yu H, et al. Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol 2014;2:146–50.

[32] Poi MJ, Berger M, Lustberg M, et al. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer 2013;21:2679–86.

[33] Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552–9.

[34] Parasar B, Edwards A, Mehta R, et al. PROCLAIM: A phase III study of docetaxel plus cisplatin, or paclitaxel or vinorelbine in the treatment of advanced non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2003;21:2004–10.

[35] Poi MJ, Berger M, Lustberg M, et al. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer 2013;21:2679–86.

[36] Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552–9.

[37] Donnelly JG. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Thor Drug Monit 2004;26:231–5.

[38] de Jong FA, Marsh S, Mathijsen RH, et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004;10:5889–94.

[39] Bellon JR, Lindley KL, Ellis GK, et al. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys 2000;46:393–7.